158 related articles for article (PubMed ID: 20485165)
1. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
2. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
4. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
5. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
8. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
9. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
10. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
11. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
Swisher E
Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
[TBL] [Abstract][Full Text] [Related]
12. [Role of oncogenetics in the treatment of breast and ovarian cancer].
Langmár Z; Németh M
Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
[No Abstract] [Full Text] [Related]
13. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
15. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
17. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
18. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
19. Combining carefully selected drug, patient genetics may lead to total tumor death.
Tuma RS
J Natl Cancer Inst; 2007 Oct; 99(20):1505-6, 1509. PubMed ID: 17925530
[No Abstract] [Full Text] [Related]
20. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations.
Ragupathy K; Ferguson M
J Obstet Gynaecol; 2011; 31(2):178-9. PubMed ID: 21281038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]